2026-05-22T00:07:06Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/252102024-11-28T15:13:08Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Perez, Marco
author
Peinado-Serrano, Javier
author
Garcia-Heredia, Jose Manuel
author
Felipe-Abrio, Irene
author
Tous, Cristina
author
Ferrer, Irene
author
Martin-Broto, Javier
author
Saez, Carmen
author
Carnero, Amancio
author
Perez, Marco
author
Peinado-Serrano, Javier
author
Garcia-Heredia, Jose Manuel
author
Felipe-Abrio, Irene
author
Tous, Cristina
author
Ferrer, Irene
author
Martin-Broto, Javier
author
Saez, Carmen
author
Carnero, Amancio
2024-10-23T09:08:08Z
2024-10-23T09:08:08Z
2016
10.18632/oncotarget.11475
1949-2553
Oncotarget
http://hdl.handle.net/10668/10392
27563810
https://hdl.handle.net/20.500.12105/25210
Sarcomas are malignant tumors accounting for a high percentage of cancer morbidity and mortality in children and young adults. Surgery and radiation therapy are the accepted treatments for most sarcomas; however, patients with metastatic disease are treated with systemic chemotherapy. Many tumors display marginal levels of chemoresponsiveness, and new treatment approaches are needed. MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. The levels of MAP17 could be used as a prognostic marker to predict the response to bortezomib in hematological malignancies and in breast tumors. Therefore, we analyzed the expression of this oncogene in sarcomas and its relationship with clinico-pathological features, as well as tested whether it can be used as a new biomarker to predict the therapeutic response to bortezomib and new therapies for sarcomas. We found that the levels of MAP17 were related to clinical features and poor survival in a cohort of 69 patients with different sarcoma types, not being restricted to any special subtype of tumor. MAP17 expression is associated with poor overall survival (p
eng
MAP17
Biomarker
Bortezomib
Sarcomas
PDX
Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1)
research article